These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23285063)

  • 61. Tetramerizing tGCN4 domain facilitates production of Influenza A H1N1 M2e higher order soluble oligomers that show enhanced immunogenicity
    Samal S; Shrivastava T; Sonkusre P; Rizvi ZA; Kumar R; Ahmed S; Vishwakarma P; Yadav N; Bansal M; Chauhan K; Pokhrel S; Das S; Tambare P; Awasthi A
    J Biol Chem; 2020 Oct; 295(42):14352-14366. PubMed ID: 32817314
    [TBL] [Abstract][Full Text] [Related]  

  • 62. rM2e-ΔPly protein immunization induces protection against influenza viruses and its co-infection with Streptococcus pneumoniae in mice.
    Guo T; Xiao J; Li L; Xu W; Yuan Y; Yin Y; Zhang X
    Mol Immunol; 2022 Dec; 152():86-96. PubMed ID: 36306645
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A universal influenza A vaccine based on adenovirus expressing matrix-2 ectodomain and nucleoprotein protects mice from lethal challenge.
    Zhou D; Wu TL; Lasaro MO; Latimer BP; Parzych EM; Bian A; Li Y; Li H; Erikson J; Xiang Z; Ertl HC
    Mol Ther; 2010 Dec; 18(12):2182-9. PubMed ID: 20877342
    [TBL] [Abstract][Full Text] [Related]  

  • 64. CD40 ligand preferentially modulates immune response and enhances protection against influenza virus.
    Hashem AM; Gravel C; Chen Z; Yi Y; Tocchi M; Jaentschke B; Fan X; Li C; Rosu-Myles M; Pereboev A; He R; Wang J; Li X
    J Immunol; 2014 Jul; 193(2):722-34. PubMed ID: 24928989
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages.
    Deng L; Ibañez LI; Van den Bossche V; Roose K; Youssef SA; de Bruin A; Fiers W; Saelens X
    PLoS One; 2015; 10(5):e0126650. PubMed ID: 25973787
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes.
    Wibowo N; Hughes FK; Fairmaid EJ; Lua LH; Brown LE; Middelberg AP
    Vaccine; 2014 Jun; 32(29):3651-5. PubMed ID: 24795225
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein.
    Guo L; Zheng M; Ding Y; Li D; Yang Z; Wang H; Chen Q; Sui Z; Fang F; Chen Z
    Arch Virol; 2010 Nov; 155(11):1765-75. PubMed ID: 20652335
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70(359-610) in prokaryotic system as a fusion protein.
    Ebrahimi SM; Tebianian M
    Mol Biol Rep; 2010 Jul; 37(6):2877-83. PubMed ID: 19813102
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Influenza A viruses: why focusing on M2e-based universal vaccines.
    Ebrahimi SM; Tebianian M
    Virus Genes; 2011 Feb; 42(1):1-8. PubMed ID: 21082230
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A boosting skin vaccination with dissolving microneedle patch encapsulating M2e vaccine broadens the protective efficacy of conventional influenza vaccines.
    Zhu W; Pewin W; Wang C; Luo Y; Gonzalez GX; Mohan T; Prausnitz MR; Wang BZ
    J Control Release; 2017 Sep; 261():1-9. PubMed ID: 28642154
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors.
    Petukhova NV; Gasanova TV; Stepanova LA; Rusova OA; Potapchuk MV; Korotkov AV; Skurat EV; Tsybalova LM; Kiselev OI; Ivanov PA; Atabekov JG
    Curr Pharm Des; 2013; 19(31):5587-600. PubMed ID: 23394564
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Induction of cross-protection against influenza A virus by DNA prime-intranasal protein boost strategy based on nucleoprotein.
    Luo J; Zheng D; Zhang W; Fang F; Wang H; Sun Y; Ding Y; Xu C; Chen Q; Zhang H; Huang D; Sun B; Chen Z
    Virol J; 2012 Nov; 9():286. PubMed ID: 23173785
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A universal influenza A vaccine based on the extracellular domain of the M2 protein.
    Neirynck S; Deroo T; Saelens X; Vanlandschoot P; Jou WM; Fiers W
    Nat Med; 1999 Oct; 5(10):1157-63. PubMed ID: 10502819
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hexon-modified recombinant E1-deleted adenovirus vectors as dual specificity vaccine carriers for influenza virus.
    Zhou D; Wu TL; Emmer KL; Kurupati R; Tuyishime S; Li Y; Giles-Davis W; Zhou X; Xiang Z; Liu Q; Ratcliffe SJ; Ertl HC
    Mol Ther; 2013 Mar; 21(3):696-706. PubMed ID: 23229092
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse.
    Mozdzanowska K; Zharikova D; Cudic M; Otvos L; Gerhard W
    Virol J; 2007 Oct; 4():118. PubMed ID: 17974006
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice.
    Zhou C; Zhou L; Chen YH
    Vaccine; 2012 May; 30(23):3463-9. PubMed ID: 22446634
    [TBL] [Abstract][Full Text] [Related]  

  • 77. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity.
    Liu W; Peng Z; Liu Z; Lu Y; Ding J; Chen YH
    Vaccine; 2004 Dec; 23(3):366-71. PubMed ID: 15530682
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Improved design and intranasal delivery of an M2e-based human influenza A vaccine.
    De Filette M; Fiers W; Martens W; Birkett A; Ramne A; Löwenadler B; Lycke N; Jou WM; Saelens X
    Vaccine; 2006 Nov; 24(44-46):6597-601. PubMed ID: 16814430
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge.
    Fu TM; Guan L; Friedman A; Schofield TL; Ulmer JB; Liu MA; Donnelly JJ
    J Immunol; 1999 Apr; 162(7):4163-70. PubMed ID: 10201942
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice.
    Wang W; Li R; Deng Y; Lu N; Chen H; Meng X; Wang W; Wang X; Yan K; Qi X; Zhang X; Xin W; Lu Z; Li X; Bian T; Gao Y; Tan W; Ruan L
    Clin Vaccine Immunol; 2015 Jun; 22(6):618-30. PubMed ID: 25834017
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.